NCT06300502 2026-04-22
Assessing the Efficacy of Repeat, Monthly Treatments of Deoxycholate for NF1 Associated Cutaneous Neurofibromas (cNFs)
Massachusetts General Hospital
Phase 1 Enrolling by invitation
Clinical Trials
26 trialsNCT07353294 2026-04-22
Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1 Enrolling by invitation
NCT07488312 2026-04-20
LUCENT-GC-01
Qilu Hospital of Shandong University
Phase 1 Enrolling by invitation
NCT06788509 2026-04-13
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Janssen Research & Development, LLC
Phase 1 Enrolling by invitation
NCT05635591 2026-04-08
KSD-101 Therapy for EBV-associated Haematologic Neoplasms: an Exploratory Clinical Trial
Tongji Hospital
Phase 1 Enrolling by invitation
NCT07218003 2026-03-23
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Rondo Therapeutics
Phase 1 Enrolling by invitation
NCT05700461 2026-03-20
Drug Screening Using Novel IMD in Renal Cell Carcinoma
Brigham and Women's Hospital
Phase 1 Enrolling by invitation
NCT07080463 2026-03-10
VascuLens RCT
University of British Columbia
Phase 1 Enrolling by invitation
NCT06508138 2026-03-06
J21112LINKED
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Enrolling by invitation
NCT05746104 2026-01-22
Second Window Indocyanine Green for All Nervous System Tumors
Abramson Cancer Center at Penn Medicine
Phase 1 Enrolling by invitation
NCT06215846 2025-11-26
A Clinical Study Evaluating the Safety and Efficacy of BioTTT001 in Patients With Malignant Solid Tumors
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Phase 1 Enrolling by invitation
NCT07014462 2025-10-06
DLIT-AML
University of Vermont
Phase 1 Enrolling by invitation
NCT05423977 2025-09-30
Study of ZV0203 in Patients With HER2-Positive Advanced Solid Tumors
Hangzhou Adcoris Biopharmacy Co., Ltd
Phase 1 Enrolling by invitation
NCT06674538 2025-09-22
Clinical Trial to Treat Stage IV Cancer Patients
Moonshot Antibodies
Phase 1 Enrolling by invitation
NCT06882876 2025-09-19
JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study
Xiangya Hospital of Central South University
Phase 1 Enrolling by invitation
NCT07168486 2025-09-11
CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas
University of Maryland, Baltimore
Phase 1 Enrolling by invitation
NCT05937269 2025-09-09
Assessing Impact of Early Physiotherapy on Lymphatic Dysfunction in Head and Neck Cancer Survivorship
The University of Texas Health Science Center, Houston
Phase 1 Enrolling by invitation
NCT06827782 2025-08-15
Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Enrolling by invitation
NCT07053904 2025-07-08
Phase I Open-Label Study of P1101 Followed by P1801 in Advanced Solid Tumors
PharmaEssentia
Phase 1 Enrolling by invitation
NCT06896110 2025-06-26
Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma
University of Iowa
Phase 1 Enrolling by invitation
NCT03170141 2025-01-20
Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme
Shenzhen Geno-Immune Medical Institute
Phase 1 Enrolling by invitation
NCT03054792 2024-12-13
Molecular-Functional Imaging of Hypoxia in Childhood Sarcomas
The Hospital for Sick Children
Phase 1 Enrolling by invitation
NCT06169579 2024-11-15
An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers
Shenzhen NewDEL Biotech, Co., Ltd
Phase 1 Enrolling by invitation
NCT06671691 2024-11-04
DESERT-I
Universitat de les Illes Balears
Phase 1 Enrolling by invitation
NCT06616727 2024-09-27
The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM
Shanghai Simnova Biotechnology Co.,Ltd.
Phase 1 Enrolling by invitation
NCT06205082 2024-03-01
A Phase I Clinical Trial to Evaluate LIT-00814 Tablets in Patients With Advanced Solid Tumor
LittDD Medicines Ltd
Phase 1 Enrolling by invitation